No Data
Express News | Kezar Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Express News | Kezar Life Sciences-Eligible for Additional 180 Calendar Day Period, or Until Nov 25 to Regain Compliance With Nasdaq Minimum Bid Price Requirement
Express News | Kezar Life Sciences Inc -Notified by Nasdaq in Letter Dated May 31, Co’s Application to Transfer to Nasdaq Capital Market Was Approved
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk,
Hold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy Concerns
Express News | Kezar Life Sciences Q1 EPS $(0.30) Beats $(0.33) Estimate